BRPI0414791A - derivados de purina inibidores da replicação do hiv - Google Patents

derivados de purina inibidores da replicação do hiv

Info

Publication number
BRPI0414791A
BRPI0414791A BRPI0414791-0A BRPI0414791A BRPI0414791A BR PI0414791 A BRPI0414791 A BR PI0414791A BR PI0414791 A BRPI0414791 A BR PI0414791A BR PI0414791 A BRPI0414791 A BR PI0414791A
Authority
BR
Brazil
Prior art keywords
formula
radical
purine derivatives
hiv replication
compound
Prior art date
Application number
BRPI0414791-0A
Other languages
English (en)
Inventor
Paul Adriaan Jan Janssen
Marc Rene De Jonge
Lucien Maria Henricus Koymans
Frederik Frans Desire Daeyaert
Jan Heeres
Hendrik Maarten Vinkers
Ruben Gerardus George Leenders
Dirk Alfons Leo Vandenput
Paulus Joannes Lewi
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0414791A publication Critical patent/BRPI0414791A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"DERIVADOS DE PURINA INIBIDORES DA REPLICAçãO DO HIV". A presente invenção diz respeito ao uso de um composto de fórmula (I) para a fabricação de um medicamento para a prevenção ou o tratamento de infecção por HIV em que o composto de fórmula (I) é um composto de fórmula (I), um N-óxido, um sal de adição farmaceuticamente aceitável, uma amina quaternária ou uma forma estereoquimicamente isomérica deste, em que A e B cada um representa um radical de fórmula (a) ou (b) e, em que -C-D- representa um radical bivalente de fórmula -N=CH-NR¬ 17¬-(c-1); ou -NR¬ 17¬-CH=N-(c-2); contanto que quando A representa um radical de fórmula (a) então B representa um radical de fórmula (b) e quando A representa um radical de fórmula (b) então B representa um radical de fórmula (a).
BRPI0414791-0A 2003-09-25 2004-09-21 derivados de purina inibidores da replicação do hiv BRPI0414791A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0350659 2003-09-25
PCT/EP2004/052262 WO2005028479A2 (en) 2003-09-25 2004-09-21 Hiv replication inhibiting purine derivatives

Publications (1)

Publication Number Publication Date
BRPI0414791A true BRPI0414791A (pt) 2006-11-21

Family

ID=34354400

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414791-0A BRPI0414791A (pt) 2003-09-25 2004-09-21 derivados de purina inibidores da replicação do hiv

Country Status (19)

Country Link
US (1) US8026245B2 (pt)
EP (1) EP1668011B1 (pt)
JP (1) JP5506751B2 (pt)
KR (1) KR20060121878A (pt)
CN (1) CN100475815C (pt)
AP (1) AP2006003517A0 (pt)
AT (1) ATE500254T1 (pt)
AU (1) AU2004274185B2 (pt)
BR (1) BRPI0414791A (pt)
CA (1) CA2535313C (pt)
DE (1) DE602004031641D1 (pt)
EA (1) EA009734B1 (pt)
ES (1) ES2361835T3 (pt)
IL (1) IL174467A0 (pt)
MX (1) MXPA06002069A (pt)
NO (1) NO20061788L (pt)
TW (1) TW200518758A (pt)
WO (1) WO2005028479A2 (pt)
ZA (1) ZA200602440B (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
US8178671B2 (en) 2003-07-30 2012-05-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
EP1720877A4 (en) * 2004-03-02 2009-11-04 Neurogen Corp ANALOGUES OF PURINS ARYL SUBSTITUTION
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
MX2007002236A (es) 2004-08-25 2007-07-09 Ardea Biosciences Inc S-triazolil-alfa-mercaptoacetanilidas como inhibidores de transcriptasa inversa de virus de inmunodeficiencia humana.
JP5043668B2 (ja) 2004-09-20 2012-10-10 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
BRPI0515489A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase
AU2005329423A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
BRPI0515500A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados piridazina para inibição de estearoil-coa-desaturase
AR051092A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
EP1799668A1 (en) 2004-09-20 2007-06-27 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
US7544672B2 (en) 2005-03-30 2009-06-09 Conforma Therapeutics Corporation Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors
CA2607021C (en) * 2005-05-05 2013-10-29 Ardea Biosciences, Inc. Diaryl-purines, -azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
AU2006261527B2 (en) * 2005-05-16 2012-11-22 Prometic Pharma Smt Limited Purine derivatives and their use for treatment of autoimmune diseases
CN101208089A (zh) 2005-06-03 2008-06-25 泽农医药公司 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP1904457B1 (en) 2005-06-08 2017-09-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
CA2668997C (en) 2006-11-09 2012-10-09 Ardea Biosciences, Inc. 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors
JP2010518014A (ja) 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用な２−アミノピリジン誘導体
TWI415840B (zh) 2007-11-27 2013-11-21 Ardea Biosciences Inc 新穎化合物、組合物及使用方法
EP2220091B1 (en) 2007-12-14 2012-07-25 Ardea Biosciences, Inc. Reverse transcriptase inhibitors
NZ590784A (en) 2008-07-23 2012-12-21 Vertex Pharma Pyrazolopyridine kinase inhibitors
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010011768A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
MX2011001319A (es) 2008-08-06 2011-04-05 Vertex Pharma Inhibidores de aminopiridina cinasa.
JP5627675B2 (ja) 2009-05-06 2014-11-19 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ピラゾロピリジン
BR112012011147A2 (pt) 2009-11-12 2021-09-08 F.Hoffmann-La Roche Ag Composto, composição farmacêutica e uso de um composto.
AU2011209651A1 (en) 2010-01-27 2012-08-09 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
AU2011209649A1 (en) 2010-01-27 2012-08-09 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
CA2787315A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
WO2011103457A1 (en) 2010-02-18 2011-08-25 Concert Pharmaceuticals Inc. Pyrimidine derivatives
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
FR2962438B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
CN103570688B (zh) * 2012-07-19 2016-06-08 中国科学院上海药物研究所 2，5-二氨甲基吡嗪类化合物、其药物组合物、制备方法和用途
US10016439B2 (en) 2014-01-31 2018-07-10 Ono Pharmaceutical Co., Ltd. Fused imidazole compounds
CA2971558C (en) 2014-12-18 2023-03-07 Nissan Chemical Industries, Ltd. Ketone or oxime compound, and herbicide
AU2017345736B2 (en) * 2016-10-21 2022-04-07 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
WO2020084142A1 (en) * 2018-10-25 2020-04-30 Minakem Process for the preparation of rilpivirine
CN110526873B (zh) * 2019-08-15 2022-09-16 复旦大学 氰乙烯基取代的苯并二芳基嘧啶类化合物及其制备方法和用途
CN114805369B (zh) * 2022-05-30 2023-05-16 自贡市第四人民医院(自贡市急救中心) 一种2，6-二取代嘌呤类化合物及制备方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
NZ322907A (en) 1995-11-23 1998-12-23 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
SK287996B6 (sk) 1998-03-27 2012-09-03 Janssen Pharmaceutica N. V. Pyrimide compound, pharmaceutical composition the compound is comprised, method for preparation thereof, combination and product containing the composition and use of the pyrimide compound
HU230394B1 (hu) 1998-11-10 2016-04-28 Janssen Pharmaceutica N.V. HIV-vírus szaporodását gátló pirimidin-származékok
US6414147B1 (en) * 1998-12-23 2002-07-02 Neurogen Corporation 2-amino-9-alkylpurines: GABA brain receptor ligands
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
CZ20022353A3 (cs) * 2000-01-07 2003-02-12 Universitaire Instelling Antwerpen Deriváty purinu, způsob jejich přípravy a jejich použití
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US6897307B2 (en) * 2002-03-28 2005-05-24 Novartis Ag Process for preparing 2,6-diaminopurine derivatives
MXPA06001758A (es) * 2003-08-15 2006-08-11 Irm Llc Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk.
CA2607021C (en) * 2005-05-05 2013-10-29 Ardea Biosciences, Inc. Diaryl-purines, -azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv

Also Published As

Publication number Publication date
IL174467A0 (en) 2006-08-01
JP2012006945A (ja) 2012-01-12
NO20061788L (no) 2006-04-24
EP1668011A2 (en) 2006-06-14
AU2004274185A1 (en) 2005-03-31
EA009734B1 (ru) 2008-02-28
DE602004031641D1 (de) 2011-04-14
ES2361835T3 (es) 2011-06-22
US8026245B2 (en) 2011-09-27
CA2535313A1 (en) 2005-03-31
KR20060121878A (ko) 2006-11-29
ZA200602440B (en) 2007-09-26
MXPA06002069A (es) 2006-05-19
EP1668011B1 (en) 2011-03-02
JP4825672B2 (ja) 2011-11-30
EA200600648A1 (ru) 2006-08-25
WO2005028479A2 (en) 2005-03-31
JP2007506707A (ja) 2007-03-22
JP5506751B2 (ja) 2014-05-28
WO2005028479A3 (en) 2005-06-16
CN1856496A (zh) 2006-11-01
TW200518758A (en) 2005-06-16
CA2535313C (en) 2012-07-17
US20060293330A1 (en) 2006-12-28
ATE500254T1 (de) 2011-03-15
CN100475815C (zh) 2009-04-08
AP2006003517A0 (en) 2006-02-28
AU2004274185B2 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
BRPI0414791A (pt) derivados de purina inibidores da replicação do hiv
AR087241A2 (es) Derivados de 6-oh-4h-benzo[1,4]oxazin-3-ona para el tratamiento de la enfermedad pulmonar obstructiva cronica
BRPI0407732A (pt) pirimidinas e triazinas inibidoras da replicação de hiv
BRPI0407329A (pt) Derivados de pirimidina para a prevenção de infecção de hiv
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
CY1109681T1 (el) Υποκατεστημενα παραγωγα κιναζολινης ως αναστολεις των κινασων aurora
UY27222A1 (es) Pirazolopirimidinas como agentes terapéuticos
UY27226A1 (es) Pirazolopirimidinas como agentes terapéuticos
BRPI0411900B8 (pt) compostos e composições farmacêuticas compreendendo os mesmos
BR0112395A (pt) Derivados de benzotiazol
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
EA200601654A1 (ru) Ингибиторы интегразы вич
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
TW200624431A (en) Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
JP2006508953A5 (pt)
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
BRPI0407097A (pt) Antagonista do casr
BRPI0417268A (pt) benzimidazóis que contêm morfolinila, como inibidores da replicação de vìrus sinciciais respiratórios
BR0113590A (pt) 7-oxo-piridopirimidinas
BRPI0607214B8 (pt) derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação
BRPI0406673A (pt) Método para o tratamento ou profilaxia e composição para uso no tratamento ou profilaxia de um ou mais sintomas de uma infecção por herpes viral em um indivìduo, e, uso de uma composição compreendendo um sal citrato e/ou um succinato
PT1156805E (pt) Utilizacao de sistenas piliciclicos de tiazole para a fabricacao de medicamentospara a profilaxia ou o tratamento de obesidade
BRPI0409217A (pt) derivados e análogos antimicrobianos da [3.1.0]bicicloexilfeniloxazolidinona
TW200736220A (en) Pyridylsulfonamide derivatives, their manufacture and use as pharmaceutical agents
DK1411956T3 (da) Anvendelse af oversulfaterede polysaccharider som inhibitorer af HIV

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]